{"nctId":"NCT01570751","briefTitle":"A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin","startDateStruct":{"date":"2012-04"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"count":145,"armGroups":[{"label":"IDeg followed by IGlar","type":"EXPERIMENTAL","interventionNames":["Drug: insulin degludec","Drug: insulin glargine"]},{"label":"IGlar followed by IDeg","type":"EXPERIMENTAL","interventionNames":["Drug: insulin degludec","Drug: insulin glargine"]}],"interventions":[{"name":"insulin degludec","otherNames":[]},{"name":"insulin glargine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 2 diabetes\n* Current treatment with once daily insulin glargine in vials with a daily dose equal to or above 65 U and equal to or below 100 U\n* Current treatment with a stable dose of metformin plus/minus one additional oral antidiabetic drug (OAD) for at least 12 weeks\n* Glycosylated haemoglobin (HbA1c) equal to or above 7.5%\n\nExclusion Criteria:\n\n* Current treatment with insulin other than insulin glargine in vials\n* Treatment with thiazolidinediones or glucagon-like peptide-1 (GLP-1) receptor agonists within 12 weeks\n* Stroke; heart failure; myocardial infarction; unstable angina pectoris; coronary arterial bypass graft or angioplasty\n* Suffer from cancer (except basal cell skin cancer and squamous-cell cancer)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline (Visit 18) in Glycosylated Haemoglobin (HbA1c) at the End of Each 16 Week Treatment Period","description":"Values for change in HbA1c after each 16 weeks of treatment periods A and B.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"1.1"},{"groupId":"OG001","value":"-0.1","spread":"1.1"}]}]}]},{"type":"SECONDARY","title":"Change in Patient Reported Outcome (PRO) Scores From Baseline to the End of Each 16 Week Treatment Period","description":"Changes in subjects quality of life and insulin device satisfaction were evaluated using the following PROs: the Short-Form 36 Health Survey version 2 (SF-36) and the Treatment Related Impact Measure-Diabetes Device (TRIM-DD). PRO total scores were measured from baseline to the end of each 16-week treatment period. Responses were measured on a scale of 0 to 100, where higher scores indicated a better quality of life and higher insulin device satisfaction on the SF-36 and TRIM-DD questionnaires, respectively.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"7.7"},{"groupId":"OG001","value":"-0.6","spread":"7.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"9.3"},{"groupId":"OG001","value":"0.4","spread":"10.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.0","spread":"19.1"},{"groupId":"OG001","value":"3.5","spread":"19.1"}]}]}]},{"type":"SECONDARY","title":"Change in PRO Scores From the End of Treatment Period A Until After 4 Weeks of Treatment in Treatment Period B","description":"SF-36 and TRIM-DD total scores were measured at the end of treatment A (week 16) and 4 weeks into treatment B (week 20). Responses were measured on a scale of 0 to 100, where higher scores indicated a better quality of life and higher insulin device satisfaction on the SF-36 and TRIM-DD questionnaires, respectively.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"7.07"},{"groupId":"OG001","value":"0.60","spread":"6.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.61","spread":"8.88"},{"groupId":"OG001","value":"0.21","spread":"8.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.24","spread":"19.89"},{"groupId":"OG001","value":"-6.25","spread":"11.10"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Central Laboratory Measured Fasting Plasma Glucose (FPG) at the End of Each 16 Week Treatment Period","description":"Values of FPG in mmol/L from baseline to each 16 weeks of treatment periods.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"4.2"},{"groupId":"OG001","value":"-0.0","spread":"4.4"}]}]}]},{"type":"SECONDARY","title":"Change in FPG From the End of Treatment Period A Until After 4 Weeks of Treatment in Treatment Period B","description":"Values of FPG in mmol/L from the end of treatment period A until after 4 weeks of treatment in treatment period B.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.78","spread":"3.41"},{"groupId":"OG001","value":"0.19","spread":"4.40"}]}]}]},{"type":"SECONDARY","title":"Number of Adverse Events (AEs)","description":"Number of treatment emergent adverse events (TEAEs) from week 0 to week 16 of the randomised treatment periods. A TEAE was defined as an event that had onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment. TEAEs were attributed to the treatment given in the period in which the event occurred.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":null},{"groupId":"OG001","value":"111","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":140},"commonTop":["Nasopharyngitis"]}}}